Pure Global AI
NCT06145412Recruiting

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

A Phase II Trial of Xevinapant in Combination With Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer
Memorial Sloan Kettering Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Head and Neck Cancer
Drug/Device/Intervention
Xevinapan
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Uniondale, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Nov 16, 2023
End date
Nov 01, 2026
Enrollment
54 participants
Primary outcome

Progression Free Survival

Summary

The purpose of this study is to test whether treatment with Xevinapant added to standard
 chemoradiation after surgery is an effective treatment for people with high-risk head and
 neck cancers.

ICD-10 classifications
Malignant neoplasm of other and ill-defined sites: Head, face and neckMalignant neoplasm: Skin of scalp and neckMalignant neoplasm: Connective and soft tissue of head, face and neckCarcinoma in situ: Skin of scalp and neckSecondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06145412
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06145412 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.